Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Barentz International, a leading global life science and specialty performance ingredients distributor, signed a distribution agreement with Ashland, Inc. (ASH) that covers its portfolio of pharmaceutical and nutraceutical products in Ireland, United Kingdom, Denmark, Sweden, Norway, Finland, Iceland, Estonia, Latvia, and Lithuania effective ...
read more
SuanNutra, the nutraceutical business arm of SuanFarma, S.A., announced the formation of its subsidiary in the US, SuanNutra, Inc. to serve the North American nutraceutical ingredient market. This strategic move strengthens the company’s commitment to the American market and will bring enhanced focus and solutions to customers.
read more
Clariant unveiled a new range of advanced pharmaceutical ingredient solutions, reinforcing its commitment to the advancement of safe and efficacious medicines. The company is introducing three innovative VitiPure® excipients designed to accommodate a wide array of Active Pharmaceutical Ingredient (API) formulations and administration methods, ...
read more
Almac Pharma Services, a member of the Almac Group, announced it is entering the final phase of a $79M million investment to expand its existing drug product manufacturing capabilities at its global headquarter site in Craigavon, Northern Ireland.
read more
Botanical-Be is voluntarily recalling of all lots of Kuka Flex Forte, Capsules, Artri King, Capsules, and Reumo Flex, Capsules to the consumer level. FDA analysis has found the Kuka Flex Forte, capsules, Artri King, capsules, and Reumo Flex, capsules, to be tainted with Diclofenac.
read more
Jiangsu Hengrui Pharmaceuticals Co., Ltd has announced a significant licensing agreement with Merck KGaA, a prominent global science and technology company headquartered in Darmstadt, Germany.
read more
Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic designed to slow or stop the progression of Alzheimer's disease and related disorders.
read more
Phathom Pharmaceuticals, Inc. received FDA approval for the Prior Approval Supplement (PAS) regarding the reformulation of vonoprazan tablets for both VOQUEZNA TRIPLE PAK (consisting of vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets) and VOQUEZNA DUAL PAK (featuring vonoprazan tablets and amoxicillin capsules).
read more
A report published by MarketsandMarkets forecasts a significant expansion of the global dietary supplements market size saying it is expected to grow from $167.5 billion in 2023 to $239.4 billion by 2028, at a CAGR of 7.4%. The report underlines the market's robust growth, predicting its ascension on a global scale and showcasing its increasing ...
read more
A recent report from Allied Market Research titled "Nootropics Supplement Market: Global Opportunity Analysis and Industry Forecast, 2022–2032" reveals that the worldwide market for nootropics supplements, valued at $2.5 billion in 2022, is anticipated to surge to $4.4 billion by 2032, experiencing a compound annual growth rate (CAGR) of 6.3% from ...
read more
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced a strategic plan to prioritize key programs, expand manufacturing capabilities, and streamline business operations.
read more
Phathom Pharmaceuticals, Inc. has received approval from the FDA for VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg doses.
read more
A study from Transparency Market Research Inc. reports that the global empty capsules market was valued at US$ 2.1 Bn in 2021 and is projected to expand at a CAGR of 7.6% from 2022 to 2031. Advancement in empty capsule production technology is likely to pave the way for advanced drug delivery systems for a range of medicinal products.
read more
Noramco, a leading global manufacturer of active pharmaceutical ingredients (APIs), with expertise in controlled substances, has successfully finalized the acquisition of the Cambrex Drug Product Business Unit, formerly known as Halo Pharmaceuticals.
read more
Teva Pharmaceutical Industries Ltd. has announced the appointment of Dr. R. Ananthanarayanan (Ananth) as the CEO of its Teva Active Pharmaceutical Ingredients business (Teva API). Dr. Ananth will assume his role on November 27, 2023, and will be based at Teva's U.S. headquarters in Parsippany, NJ.
read more